NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Carlson LM, Dean J, Stanek J, et al. Provisional Peer-Reviewed Toxicity Values for 3,5-Dinitroaniline (CASRN 618-87-1). Cincinnati (OH): U.S. Environmental Protection Agency; 2021 Aug.
Provisional Peer-Reviewed Toxicity Values for 3,5-Dinitroaniline (CASRN 618-87-1).
Show detailsThe lack of toxicity data precludes direct development of cancer or noncancer provisional reference values for 3,5-dinitroaniline. However, screening provisional reference dose (p-RfD) values and screening provisional reference concentration (p-RfC) values are derived based on available data for structurally similar compounds (see Appendix A).
3.1. DERIVATION OF ORAL REFERENCE DOSES
There are no data on the effects of 3,5-dinitroaniline in humans or animals exposed orally. Because of the lack of any available data for 3,5-dinitroaniline, subchronic and chronic p-RfDs cannot be derived directly. Instead, screening p-RfDs are derived in Appendix A using an alternative analogue approach. Based on the overall analogue approach presented in Appendix A, 4-nitroaniline is selected as the most appropriate analogue for 3,5-dinitroaniline for deriving a screening subchronic and chronic p-RfD.
3.2. DERIVATION OF INHALATION REFERENCE CONCENTRATIONS
There are no data on the effects of 3,5-dinitroaniline in humans or animals exposed by inhalation. The absence of relevant inhalation data precludes deriving p-RfCs for 3,5-dinitroaniline directly. Instead, screening p-RfCs are derived in Appendix A using an alternative analogue approach. Based on the overall analogue approach presented in Appendix A, 4-nitroaniline is selected as the most appropriate analogue for 3,5-dinitroaniline for deriving a screening subchronic and chronic p-RfC.
3.3. SUMMARY OF PROVISIONAL REFERENCE VALUES
The noncancer provisional reference values for 3,5-dinitroaniline are summarized in Table 5.
Table 5
Summary of Noncancer Reference Values for 3,5-Dinitroaniline (CASRN 618-87-1).
3.4. CANCER WEIGHT-OF-EVIDENCE DESCRIPTOR
Under the U.S. EPA Cancer Guidelines (U.S. EPA, 2005a), there is “Inadequate Information to Assess the Carcinogenic Potential” of 3,5-dinitroaniline (see Table 6). No relevant studies are available in humans or animals. Within the current U.S. EPA Cancer Guidelines (U.S. EPA, 2005a), there is no standard methodology to support the identification of a weight-of-evidence (WOE) descriptor and derivation of provisional cancer risk estimates for data-poor chemicals using an analogue approach. In the absence of an established framework, a screening evaluation of potential carcinogenicity is provided using the methodology described in Appendix B. This evaluation determined that there is a qualitative level of concern for potential carcinogenicity of 3,5-dinitroaniline (see Appendix C).
Table 6
Cancer WOE Descriptor for 3,5-Dinitroaniline (CASRN 618-87-1).
- DERIVATION OF PROVISIONAL VALUES - Provisional Peer-Reviewed Toxicity Values for...DERIVATION OF PROVISIONAL VALUES - Provisional Peer-Reviewed Toxicity Values for 3,5-Dinitroaniline (CASRN 618-87-1)
- REVIEW OF POTENTIALLY RELEVANT DATA (NONCANCER AND CANCER) - Provisional Peer-Re...REVIEW OF POTENTIALLY RELEVANT DATA (NONCANCER AND CANCER) - Provisional Peer-Reviewed Toxicity Values for 3,5-Dinitroaniline (CASRN 618-87-1)
- Myrmarachne spissa voucher PUZ-IMP-1073 cytochrome c oxidase subunit 1 (COI) gen...Myrmarachne spissa voucher PUZ-IMP-1073 cytochrome c oxidase subunit 1 (COI) gene, partial cds; mitochondrialgi|1240504340|gb|KY587560.1|Nucleotide
Your browsing activity is empty.
Activity recording is turned off.
See more...